<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Arch Womens Ment Health</journal-id><journal-id journal-id-type="iso-abbrev">Arch Womens Ment Health</journal-id><journal-title-group><journal-title>Archives of Women's Mental Health</journal-title></journal-title-group><issn pub-type="ppub">1434-1816</issn><issn pub-type="epub">1435-1102</issn><publisher><publisher-name>Springer Vienna</publisher-name><publisher-loc>Vienna</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39085616</article-id><article-id pub-id-type="pmc">PMC11785814</article-id>
<article-id pub-id-type="publisher-id">1487</article-id><article-id pub-id-type="doi">10.1007/s00737-024-01487-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>Post-traumatic stress disorder symptomatology is associated with insomnia among women engaged in opioid use disorder treatment with buprenorphine</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4851-6260</contrib-id><name><surname>Stadtler</surname><given-names>Hannah</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9960-2404</contrib-id><name><surname>Turkson</surname><given-names>Susie</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Eglovitch</surname><given-names>Michelle</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1498-4333</contrib-id><name><surname>Svikis</surname><given-names>Dace S.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0955-9161</contrib-id><name><surname>Neigh</surname><given-names>Gretchen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5560-458X</contrib-id><name><surname>Martin</surname><given-names>Caitlin E.</given-names></name><address><email>Caitlin.martin@vcuhealth.org</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02nkdxk79</institution-id><institution-id institution-id-type="GRID">grid.224260.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0458 8737</institution-id><institution>Department of Anatomy and Neurobiology, </institution><institution>Virginia Commonwealth University, </institution></institution-wrap>Richmond, VA USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02nkdxk79</institution-id><institution-id institution-id-type="GRID">grid.224260.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0458 8737</institution-id><institution>Department of Psychology, </institution><institution>Virginia Commonwealth University, </institution></institution-wrap>Richmond, VA USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02nkdxk79</institution-id><institution-id institution-id-type="GRID">grid.224260.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0458 8737</institution-id><institution>Institute for Drug and Alcohol Studies, School of Medicine, </institution><institution>Virginia Commonwealth University, </institution></institution-wrap>Richmond, VA USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02nkdxk79</institution-id><institution-id institution-id-type="GRID">grid.224260.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0458 8737</institution-id><institution>Department of Obstetrics and Gynecology, School of Medicine, </institution><institution>Virginia Commonwealth University, </institution></institution-wrap>1101 East Marshall Street, 11th Floor, Room 11-027, Box #980034, 23298 Richmond, VA USA </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>28</volume><issue>3</issue><fpage>633</fpage><lpage>637</lpage><history><date date-type="received"><day>21</day><month>2</month><year>2024</year></date><date date-type="accepted"><day>11</day><month>6</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">This study aimed to explore the association between the degree of PTSD symptomatology and severity of insomnia symptoms in a clinical sample of women receiving buprenorphine for OUD. PTSD symptomatology was assessed via the PCL-5, and insomnia symptoms were determined via the Insomnia Severity Index. Analyses indicated that more participants experiencing clinically significant PTSD symptomatology also reported insomnia symptoms than their counterparts. Future work should investigate how holistic care (e.g., trauma-informed approaches) that addresses the overlap between trauma and sleep disturbance could inform gender-specific OUD treatment strategies in the overdose crisis.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>PTSD</kwd><kwd>Trauma</kwd><kwd>Insomnia</kwd><kwd>Buprenorphine</kwd><kwd>Women</kwd></kwd-group><funding-group><award-group><funding-source><institution>the Emory SCORE</institution></funding-source><award-id>NIH U54 AG062334</award-id><award-id>NIH U54 AG062334</award-id><award-id>NIH U54 AG062334</award-id><principal-award-recipient><name><surname>Stadtler</surname><given-names>Hannah</given-names></name><name><surname>Turkson</surname><given-names>Susie</given-names></name><name><surname>Neigh</surname><given-names>Gretchen</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000026</institution-id><institution>National Institute on Drug Abuse</institution></institution-wrap></funding-source><award-id>T32DA007027</award-id><award-id>K23DA053507</award-id><principal-award-recipient><name><surname>Eglovitch</surname><given-names>Michelle</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>the Jeanann Dunlap Foundation</institution></funding-source><award-id>the Jeanann Dunlap Foundation</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006108</institution-id><institution>National Center for Advancing Translational Sciences</institution></institution-wrap></funding-source><award-id>UM1TR004360</award-id><principal-award-recipient><name><surname>Stadtler</surname><given-names>Hannah</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>F31AG076375</award-id><principal-award-recipient><name><surname>Turkson</surname><given-names>Susie</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Austria, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par6">Medications for opioid use disorder (MOUD), like buprenorphine and methadone, reduce risk of overdose and improve quality of life for people with opioid use disorder (OUD) (Larochelle et al. <xref ref-type="bibr" rid="CR6">2018</xref>). However, return to non-prescribed opioid use and OUD treatment discontinuation rates remain high. Sleep disturbances, especially insomnia (a chronic condition defined by difficulty falling asleep or staying asleep), are common among individuals in MOUD treatment (Wilkerson and McRae-Clark <xref ref-type="bibr" rid="CR12">2021</xref>). MOUD patients face multiple biopsychosocial risk factors for insomnia, ranging from community-level social determinants like unstable housing to individual-level clinical variables (Eglovitch et al. <xref ref-type="bibr" rid="CR3">2023</xref>). Considering an example of the latter, MOUD treatments themselves are associated with neurobiological changes in sleep architecture (Huhn and Finan <xref ref-type="bibr" rid="CR4">2022</xref>). Thus, exploring the complexity underlying insomnia within the context of MOUD engagement could inform treatment innovations (Eckert and Yaggi <xref ref-type="bibr" rid="CR2">2022</xref>).</p><p id="Par7">One major risk factor for sleep disturbances, and particularly for insomnia, is post-traumatic stress disorder (PTSD). PTSD is a psychiatric condition that may occur in people who have experienced or witnessed a traumatic event or set of circumstances. PTSD has been proposed as having a bidirectional relationship with sleep issues: on days when PTSD symptoms are worse, sleep is worse, which further exacerbates PTSD symptoms and perpetuates this cycle (Slavish et al. <xref ref-type="bibr" rid="CR9">2022</xref>). However, the relationship between PTSD and insomnia symptoms among people receiving MOUD has yet to be elucidated. This relationship represents a promising area for further investigation.</p><p id="Par8">Further, differences related to sex and gender-related factors exist in PTSD, insomnia, and OUD. The lifetime prevalence of PTSD in women is twice the documented prevalence in men, and women with PTSD are more susceptible to experiencing sleep disturbances compared to men (Kilpatrick et al. <xref ref-type="bibr" rid="CR5">2013</xref>). OUD treatment trajectories differ between men and women, such as being differentially impacted by trauma histories. For example, interpersonal trauma has been found to be associated with return to substance use among women, but not among men, in buprenorphine-based OUD treatment (Martin et al. <xref ref-type="bibr" rid="CR7">2022</xref>).</p><p id="Par9">Therefore, in a clinical sample of women engaged in OUD treatment with buprenorphine, the present study: (1) reports on the prevalence of patient-reported insomnia symptoms in patients with clinically significant and subthreshold PTSD symptomatology, and (2) examines the association between the severity of PTSD symptomology and severity of insomnia symptoms. While this study was exploratory, we hypothesized that women receiving buprenorphine for OUD with comorbid PTSD symptomatologies would report worse sleep than their counterparts.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Participants and Study Design</title><p id="Par10">This study was a secondary analysis from a parent study assessing insomnia among individuals receiving buprenorphine in outpatient OUD treatment. The parent study was conducted from February 2022-September 2023. Participants within the parent study were assigned female sex at birth, diagnosed with OUD, not pregnant nor within 6 weeks postpartum, aged 18&#x02013;65, and stabilized on buprenorphine for at least 6 weeks. Detailed methods are described in Eglovitch et al. (<xref ref-type="bibr" rid="CR3">2023</xref>). All parent study participants identified as cisgender; therefore, we use the term &#x02018;women&#x02019; in the present study to refer to cisgender women.</p></sec><sec id="Sec4"><title>Measures</title><p id="Par11">The primary outcome of patient-reported insomnia symptoms were determined via the Insomnia Severity Index (ISI). The ISI is a 7-item scaled self-report tool which assesses overall sleep quality. Total scores range from 0 to 28 with higher scores indicating worse insomnia. A cutoff score of <italic>&#x0003e;&#x02009;=</italic>&#x02009;10 was used to identify clinically significant insomnia (Morin et al. <xref ref-type="bibr" rid="CR8">2011</xref>). We also report on the prevalence of individuals endorsing individual ISI items to explore specific domains of sleep disturbance.</p><p id="Par12">Clinically significant PTSD symptomatology was assessed via the PCL-5. The PCL-5 assesses the twenty DSM-5 symptoms of PTSD, with a self-report rating scale of 0&#x02013;4 for each question. A total symptom severity score is obtained from combining the scores for each of the 20 items, and ranges from 0 to 80, with higher scores indicating greater PTSD symptom severity (Weathers et al., <xref ref-type="bibr" rid="CR11">n.d.</xref>). A cutoff score of 31 was used to define clinically significant versus subthreshold PTSD symptomatology (Weathers et al., <xref ref-type="bibr" rid="CR11">n.d.</xref>).</p><p id="Par13">Demographic variables were assessed by self-report on questionnaires. The degree of social support was determined with the question: &#x0201c;In a typical week, how often do you get together with friends or relatives,&#x0201d; with answer choices: rarely/never, sometimes, or usually/always.</p></sec><sec id="Sec5"><title>Data Analysis</title><p id="Par14">Analyses were conducted with SPSS (version 28). For the first study objective, descriptive statistics were calculated by PTSD symptomatology groups. For the second objective, a multiple linear regression analysis examined the association between degree of PTSD symptomatology and insomnia symptom severity. In addition to PCL-5 score, four other variables were included in the model with the outcome being ISI total score: age, social support, receipt of behavioral treatment and psychiatric medication, which were included based on existing literature (Slavish et al. <xref ref-type="bibr" rid="CR9">2022</xref>).</p></sec></sec><sec id="Sec6"><title>Results</title><sec id="Sec7"><title>Study sample</title><p id="Par15">Among the total sample of 79 women participants (recruitment rate&#x02009;=&#x02009;76.0%), 46 reported clinically significant PTSD symptomology (58.2%), and 33 reported subthreshold PTSD symptomatology (41.8%) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The mean PCL-5 score among participants with clinically significant PTSD symptomology was 54.6 (SD&#x02009;=&#x02009;12.3), and the mean score among participants with subthreshold PTSD symptomology was 13.9 (SD&#x02009;=&#x02009;10.0) (range: 0&#x02013;80).</p><p id="Par16">PTSD groups were similar across sociodemographic variables. Both PTSD groups were receiving comparable doses of buprenorphine (M&#x02009;=&#x02009;24&#x000a0;mg for both groups) and had been in OUD treatment for long durations of time (M&#x02009;=&#x02009;56.4 months and 55.2 months, respectively). In this &#x02018;real-world&#x02019; clinical sample, non-opioid substance use was common, largely nicotine (PTSD symptomatology 71.7%; subthreshold-PTSD symptomatology 60.6%), followed by cannabis (30.4% and 54.5%) and alcohol (21.7% and 15.2%).</p></sec><sec id="Sec8"><title>Differences in insomnia symptoms between participants with clinically significant and subthreshold PTSD symptomatology</title><p id="Par17">More participants experiencing clinically significant PTSD symptomatology reported insomnia symptoms than their counterparts, including difficulty falling asleep (87% vs. 60.6%), difficulty staying asleep (89.1% vs. 69.7%) and having problems with waking up too early (93.5% vs. 66.7%). Additionally, total ISI scores were higher among participants with clinically significant PTSD symptomatology than those with subthreshold PTSD symptomatology (17.6 vs. 10.1).</p><p id="Par18">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Sociodemographic, clinical, and sleep characteristics of study sample</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Clinically significant PTSD symptomatology<break/>(<italic>n</italic>&#x02009;=&#x02009;46)<break/>M (SD) or <italic>N</italic> (%)</th><th align="left">Subthreshold PTSD symptomatology<break/>(<italic>n</italic>&#x02009;=&#x02009;33)<break/>M (SD) or <italic>N</italic> (%)</th></tr></thead><tbody><tr><td align="left">
<bold>Demographics</bold>
</td><td align="left"/><td align="left"/></tr><tr><td align="left">Age (years)</td><td align="left">35.9 (8.9)</td><td align="left">38.6 (9.4)</td></tr><tr><td align="left"><p>Race</p><p>White</p><p>Black</p><p>Other</p></td><td align="left"><p>26 (56.6%)</p><p>17 (37.0%)</p><p>3 (6.5%)</p></td><td align="left"><p>22 (66.7%)</p><p>8 (24.2%)</p><p>3 (9.1%)</p></td></tr><tr><td align="left"><p>Ethnicity</p><p>Hispanic/Latinx</p><p>Not Hispanic/Latinx</p></td><td align="left"><p>3 (6.5%)</p><p>43 (93.5%)</p></td><td align="left"><p>1 (3.0%)</p><p>32 (97.0%)</p></td></tr><tr><td align="left"><p>Employment</p><p>Employed</p><p>Unemployed</p><p>Disabled</p></td><td align="left"><p>12 (26.1%)</p><p>25 (54.3%)</p><p>9 (19.6%)</p></td><td align="left"><p>11 (33.3%)</p><p>16 (48.5%)</p><p>6 (18.2%)</p></td></tr><tr><td align="left"><p>Insurance</p><p>Public</p><p>Private</p><p>None</p></td><td align="left"><p>45 (97.8%)</p><p>1 (2.2%)</p><p>0 (0%)</p></td><td align="left"><p>26 (78.8%)</p><p>5 (15.2%)</p><p>2 (6.1%)</p></td></tr><tr><td align="left"><p>Education</p><p><italic>&#x02264;</italic> High school</p><p>&#x0003e; High school</p></td><td align="left"><p>31 (67.4%)</p><p>15 (32.6%)</p></td><td align="left"><p>21 (63.6%)</p><p>12 (36.4%)</p></td></tr><tr><td align="left">Social support (% yes)</td><td align="left">38&#x000a0;(82.6%)</td><td align="left">27 (81.8%)</td></tr><tr><td align="left">
<bold>Clinical Variables</bold>
</td><td align="left"/><td align="left"/></tr><tr><td align="left">Behavioral treatment (% yes)</td><td align="left">27 (58.7%)</td><td align="left">11 (33.3%)</td></tr><tr><td align="left">Psychiatric Medication</td><td align="left">40 (87.0%)</td><td align="left">16 (48.5%)</td></tr><tr><td align="left"><p>Past 28-day non-prescribed substance use (% yes)</p><p>&#x02003;Nicotine</p><p>&#x02003;Cannabis</p><p>&#x02003;Alcohol</p><p>&#x02003;Cocaine</p><p>&#x02003;Heroin/Fentanyl</p><p>&#x02003;Amphetamines</p><p>&#x02003;Sedatives</p></td><td align="left"><p>33 (71.7%)</p><p>14 (30.4%)</p><p>10 (21.7%)</p><p>4 (8.7%)</p><p>1 (2.2%)</p><p>2 (4.3%)</p><p>1 (2.2%)</p></td><td align="left"><p>20 (60.6%)</p><p>18 (54.5%)</p><p>5 (15.2%)</p><p>5 (15.2%)</p><p>0 (0%)</p><p>1 (3.0%)</p><p>0 (0%)</p></td></tr><tr><td align="left">
<bold>OUD Variables</bold>
</td><td align="left"/><td align="left"/></tr><tr><td align="left">Dose of buprenorphine (mg, range)</td><td align="left">24 (4&#x02013;30)</td><td align="left">24 (6&#x02013;18)</td></tr><tr><td align="left">Length of time in treatment&#x000a0;(months)</td><td align="left">56.4 (46.3)</td><td align="left">55.2 (46.5)</td></tr><tr><td align="left">
<bold>Sleep Variables</bold>
</td><td align="left"/><td align="left"/></tr><tr><td align="left">Clinically significant insomnia symptoms (ISI score&#x02009;&#x0003e;&#x02009;=&#x02009;10)</td><td align="left">40 (87.0%)</td><td align="left">16 (48.5%)</td></tr><tr><td align="left">Total ISI score (range: 0&#x02013;28)</td><td align="left">17.6 (6.2)</td><td align="left">10.1 (7.8)</td></tr><tr><td align="left">Difficulty falling asleep (% yes)</td><td align="left">40 (87.0%)</td><td align="left">20 (60.6%)</td></tr><tr><td align="left">Difficulty staying asleep (% yes)</td><td align="left">41 (89.1%)</td><td align="left">23 (69.7%)</td></tr><tr><td align="left">Problems waking up too early (% yes)</td><td align="left">43 (93.5%)</td><td align="left">22 (66.7%)</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec9"><title>Association between PTSD symptomatology and insomnia symptom severity</title><p id="Par19">The multiple regression model significantly predicted insomnia scores, <italic>F</italic> (5, 64)&#x02009;=&#x02009;4.12, <italic>p</italic>&#x02009;=&#x02009;.003, <italic>R</italic><sup>2</sup>&#x02009;=&#x02009;0.24. Together, these predictors accounted for 24.4% of the variance in insomnia scores. Degree of PTSD symptomology, <italic>t</italic> (69)&#x02009;=&#x02009;3.325, <italic>p</italic>&#x02009;=&#x02009;.001 was significantly associated with insomnia symptom severity (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par20">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Predictors of insomnia severity</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="5">Insomnia Severity Index (ISI) Total Score</th></tr><tr><th align="left"/><th align="left"/><th align="left"/><th align="left"/><th align="left" colspan="2">95% Confidence Interval for B</th></tr><tr><th align="left"/><th align="left">Beta</th><th align="left">t</th><th align="left">Sig.</th><th align="left"/><th align="left"/></tr></thead><tbody><tr><td align="left">PCL-5 Total Score</td><td align="left">4.09</td><td align="left">3.33</td><td align="left">0.001</td><td align="left">0.062</td><td align="left">0.249</td></tr><tr><td align="left">Age</td><td align="left">0.082</td><td align="left">0.734</td><td align="left">0.465</td><td align="left">&#x02212;&#x02009;0.118</td><td align="left">0.225</td></tr><tr><td align="left">Social support</td><td align="left">0.047</td><td align="left">0.390</td><td align="left">0.698</td><td align="left">-2.031</td><td align="left">3.017</td></tr><tr><td align="left">Behavioral treatment</td><td align="left">0.034</td><td align="left">0.281</td><td align="left">0.780</td><td align="left">-3.236</td><td align="left">4.294</td></tr><tr><td align="left">Psychiatric medication</td><td align="left">0.152</td><td align="left">1.251</td><td align="left">0.215</td><td align="left">-1.561</td><td align="left">6.794</td></tr></tbody></table></table-wrap>
</p></sec></sec><sec id="Sec10"><title>Discussion</title><p id="Par21">We found that PTSD was associated with insomnia symptoms in a clinical sample of women in outpatient OUD treatment. Of note, our participants had been receiving buprenorphine on average for over 4 years across PTSD groups, underscoring how mental health and sleep problems can persist across stages of OUD treatment and recovery. These data indicate that targeting PTSD within the context of emerging sleep health interventions could more broadly impact health outcomes among women receiving MOUD treatment. Notably, insomnia-related sleep disturbances were highly prevalent across both groups with clinically significant and subthreshold PTSD symptomologies, consistent with existing literature (Huhn and Finan <xref ref-type="bibr" rid="CR4">2022</xref>). Collectively, findings emphasize the importance of considering sleep disturbances in the context of long-term mental health strategies within MOUD treatment settings.</p><p id="Par22">Study findings support the notion that, because of the overlapping influences of PTSD on sleep, and sleep disturbances on behavioral treatments, individuals on MOUD likely benefit from holistic care that aims to address both PTSD and insomnia within the context of OUD treatment. An example is trauma informed care, which is a healthcare approach that frames care around a patient&#x02019;s unique history of trauma in order to address an individual&#x02019;s healthcare needs (Center for Substance Abuse Treatment (US), <xref ref-type="bibr" rid="CR1">2014</xref>). Trauma informed care includes implementing trauma screening, creating an inclusive environment to promote patient disclosure, and improving sensitive provider-patient relationships (Center for Substance Abuse Treatment (US), <xref ref-type="bibr" rid="CR1">2014</xref>). This is especially important for women in MOUD care, due to their particularly high burden of PTSD and insomnia (Slavish et al. <xref ref-type="bibr" rid="CR9">2022</xref>). Our study suggests that emerging gender-specific therapeutics targeting insomnia among MOUD patients should prioritize trauma informed care in their development and investigations to ensure patient-centeredness in clinical applicability and research.</p><p id="Par23">There were several limitations within this analysis. This study relies on cross-sectional self-report data. Additionally, many participants endorsed ongoing substance use, reflective of our &#x02018;real world&#x02019; sample of individuals in MOUD treatment. Furthermore, women were maintained on buprenorphine longer than the average length of retention in MOUD treatment, which is typically less than 6 months (Wakeman et al. <xref ref-type="bibr" rid="CR10">2020</xref>), limiting generalizability. However, our specialized study sample provides unique insight into a population highly engaged in care yet still in need of tailored interventions to improve treatment outcomes. Future research could assess if sleep disturbances change as PTSD symptomatology changes in women on MOUD, which would give further insight into the relationship among multiple risk factors for sleep disturbances.</p></sec><sec id="Sec11"><title>Conclusions</title><p id="Par24">This study investigated associations between PTSD symptoms and insomnia in a clinical sample of women engaged in outpatient OUD treatment with buprenorphine. We found that clinically significant PTSD symptomatology in this group is associated with severity of insomnia symptoms. Findings highlight the need to investigate best practices to integrate person-centered, gender-informed, targeted treatments for co-morbid conditions, such as insomnia, among this clinical population.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work is supported by the Emory SCORE award no. NIH U54 AG062334 (HS, ST, GNN), the National Institute on Aging (NIA) award no. F31AG076375 (ST), the National Institute on Drug Abuse (NIDA) award no. T32DA007027 (ME), National Institute on Drug Abuse (NIDA) award no. K23DA053507 (PI: CEM), the Jeanann Dunlap Foundation (PI: CEM), and the National Center for Advancing Translational Sciences UM1TR004360 (Virginia Commonwealth University Wright Center).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization: Dr. Caitlin E. Martin; Methodology: Dr. Caitlin E. Martin, Michelle Eglovitch; Formal analysis: Michelle Eglovitch; Investigation: Dr. Caitlin E. Martin; Writing - original draft preparation: Hannah Stadtler, Susie Turkson; Writing - review and editing: Hannah Stadtler, Susie Turkson, Michelle Eglovitch, Dr. Caitlin E. Martin, Dr. Dace Svikis; Dr. Gretchen Neigh; Funding acquisition: Dr. Caitlin E. Martin; Resources: Dr. Caitlin E. Martin; Supervision: Dr. Caitlin E. Martin, Michelle Eglovitch.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Research data are not shared.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethical approval</title><p id="Par25">All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This research study was approved by the Virginia Commonwealth University Internal Review Board (HM20023390).</p></notes><notes id="FPar3"><title>Consent to participate</title><p id="Par31">Informed consent was obtained from all individual participants included in the study.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par30">All authors declare no financial or non-financial conflict of interest. The authors alone are responsible for the content and writing of this paper.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><mixed-citation publication-type="other">Center for Substance Abuse Treatment (US) (2014) <italic>Trauma-Informed Care in Behavioral Health Services</italic>. Substance Abuse and Mental Health Services Administration (US). <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK207201/">http://www.ncbi.nlm.nih.gov/books/NBK207201/</ext-link></mixed-citation></ref><ref id="CR2"><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Eckert</surname><given-names>DJ</given-names></name><name><surname>Yaggi</surname><given-names>HK</given-names></name></person-group><article-title>Opioid Use Disorder, Sleep Deficiency, and Ventilatory Control: bidirectional mechanisms and therapeutic targets</article-title><source>Am J Respir Crit Care Med</source><year>2022</year><volume>206</volume><issue>8</issue><fpage>937</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1164/rccm.202108-2014CI</pub-id><pub-id pub-id-type="pmid">35649170</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Eckert DJ, Yaggi HK (2022) Opioid Use Disorder, Sleep Deficiency, and Ventilatory Control: bidirectional mechanisms and therapeutic targets. Am J Respir Crit Care Med 206(8):937&#x02013;949. 10.1164/rccm.202108-2014CI<pub-id pub-id-type="pmid">35649170</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Eglovitch</surname><given-names>M</given-names></name><name><surname>Parlier-Ahmad</surname><given-names>AB</given-names></name><name><surname>Legge</surname><given-names>C</given-names></name><name><surname>Chithranjan</surname><given-names>S</given-names></name><name><surname>Kolli</surname><given-names>S</given-names></name><name><surname>Violante</surname><given-names>S</given-names></name><name><surname>Dzierzewski</surname><given-names>JM</given-names></name><name><surname>Huhn</surname><given-names>AS</given-names></name><name><surname>Wilkerson</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>CE</given-names></name></person-group><article-title>Patient reported preferences for sleep interventions among women receiving buprenorphine for opioid use disorder</article-title><source>Front Psychiatry</source><year>2023</year><volume>14</volume><fpage>1244156</fpage><pub-id pub-id-type="doi">10.3389/fpsyt.2023.1244156</pub-id><pub-id pub-id-type="pmid">37779614</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Eglovitch M, Parlier-Ahmad AB, Legge C, Chithranjan S, Kolli S, Violante S, Dzierzewski JM, Huhn AS, Wilkerson A, Martin CE (2023) Patient reported preferences for sleep interventions among women receiving buprenorphine for opioid use disorder. Front Psychiatry 14:1244156. 10.3389/fpsyt.2023.1244156<pub-id pub-id-type="pmid">37779614</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Huhn</surname><given-names>AS</given-names></name><name><surname>Finan</surname><given-names>PH</given-names></name></person-group><article-title>Sleep disturbance as a therapeutic target to improve opioid use disorder treatment</article-title><source>Exp Clin Psychopharmacol</source><year>2022</year><volume>30</volume><issue>6</issue><fpage>1024</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.1037/pha0000477</pub-id><pub-id pub-id-type="pmid">34110889</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Huhn AS, Finan PH (2022) Sleep disturbance as a therapeutic target to improve opioid use disorder treatment. Exp Clin Psychopharmacol 30(6):1024&#x02013;1035. 10.1037/pha0000477<pub-id pub-id-type="pmid">34110889</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><mixed-citation publication-type="other">Kilpatrick DG, Resnick HS, Milanak ME, Miller MW, Keyes KM, Friedman MJ National Estimates of Exposure to Traumatic Events and PTSD, Prevalence Using, Criteria (2013) <italic>DSM-5</italic> PTSD Prevalence. <italic>Journal of Traumatic Stress</italic>, <italic>26</italic>(5), 537&#x02013;547. 10.1002/jts.21848</mixed-citation></ref><ref id="CR6"><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Larochelle</surname><given-names>MR</given-names></name><name><surname>Bernson</surname><given-names>D</given-names></name><name><surname>Land</surname><given-names>T</given-names></name><name><surname>Stopka</surname><given-names>TJ</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Xuan</surname><given-names>Z</given-names></name><name><surname>Bagley</surname><given-names>SM</given-names></name><name><surname>Liebschutz</surname><given-names>JM</given-names></name><name><surname>Walley</surname><given-names>AY</given-names></name></person-group><article-title>Medication for opioid Use Disorder after Nonfatal Opioid Overdose and Association with Mortality: a Cohort Study</article-title><source>Ann Intern Med</source><year>2018</year><volume>169</volume><issue>3</issue><fpage>137</fpage><pub-id pub-id-type="doi">10.7326/M17-3107</pub-id><pub-id pub-id-type="pmid">29913516</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, Bagley SM, Liebschutz JM, Walley AY (2018) Medication for opioid Use Disorder after Nonfatal Opioid Overdose and Association with Mortality: a Cohort Study. Ann Intern Med 169(3):137. 10.7326/M17-3107<pub-id pub-id-type="pmid">29913516</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>CE</given-names></name><name><surname>Parlier-Ahmad</surname><given-names>AB</given-names></name><name><surname>Beck</surname><given-names>L</given-names></name><name><surname>Thomson</surname><given-names>ND</given-names></name></person-group><article-title>Interpersonal trauma among women and men receiving buprenorphine in Outpatient Treatment for Opioid Use Disorder</article-title><source>Violence against Women</source><year>2022</year><volume>28</volume><issue>10</issue><fpage>2448</fpage><lpage>2465</lpage><pub-id pub-id-type="doi">10.1177/10778012211032715</pub-id><pub-id pub-id-type="pmid">34894888</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Martin CE, Parlier-Ahmad AB, Beck L, Thomson ND (2022) Interpersonal trauma among women and men receiving buprenorphine in Outpatient Treatment for Opioid Use Disorder. Violence against Women 28(10):2448&#x02013;2465. 10.1177/10778012211032715<pub-id pub-id-type="pmid">34894888</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Morin</surname><given-names>CM</given-names></name><name><surname>Belleville</surname><given-names>G</given-names></name><name><surname>B&#x000e9;langer</surname><given-names>L</given-names></name><name><surname>Ivers</surname><given-names>H</given-names></name></person-group><article-title>The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response</article-title><source>Sleep</source><year>2011</year><volume>34</volume><issue>5</issue><fpage>601</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1093/sleep/34.5.601</pub-id><pub-id pub-id-type="pmid">21532953</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Morin CM, Belleville G, B&#x000e9;langer L, Ivers H (2011) The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep 34(5):601&#x02013;608. 10.1093/sleep/34.5.601<pub-id pub-id-type="pmid">21532953</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Slavish</surname><given-names>DC</given-names></name><name><surname>Briggs</surname><given-names>M</given-names></name><name><surname>Fentem</surname><given-names>A</given-names></name><name><surname>Messman</surname><given-names>BA</given-names></name><name><surname>Contractor</surname><given-names>AA</given-names></name></person-group><article-title>Bidirectional associations between daily PTSD symptoms and sleep disturbances: a systematic review</article-title><source>Sleep Med Rev</source><year>2022</year><volume>63</volume><fpage>101623</fpage><pub-id pub-id-type="doi">10.1016/j.smrv.2022.101623</pub-id><pub-id pub-id-type="pmid">35367721</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Slavish DC, Briggs M, Fentem A, Messman BA, Contractor AA (2022) Bidirectional associations between daily PTSD symptoms and sleep disturbances: a systematic review. Sleep Med Rev 63:101623. 10.1016/j.smrv.2022.101623<pub-id pub-id-type="pmid">35367721</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Wakeman</surname><given-names>SE</given-names></name><name><surname>Larochelle</surname><given-names>MR</given-names></name><name><surname>Ameli</surname><given-names>O</given-names></name><name><surname>Chaisson</surname><given-names>CE</given-names></name><name><surname>McPheeters</surname><given-names>JT</given-names></name><name><surname>Crown</surname><given-names>WH</given-names></name><name><surname>Azocar</surname><given-names>F</given-names></name><name><surname>Sanghavi</surname><given-names>DM</given-names></name></person-group><article-title>Comparative effectiveness of different treatment pathways for opioid Use Disorder</article-title><source>JAMA Netw Open</source><year>2020</year><volume>3</volume><issue>2</issue><fpage>e1920622</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.20622</pub-id><pub-id pub-id-type="pmid">32022884</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM (2020) Comparative effectiveness of different treatment pathways for opioid Use Disorder. JAMA Netw Open 3(2):e1920622. 10.1001/jamanetworkopen.2019.20622<pub-id pub-id-type="pmid">32022884</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><mixed-citation publication-type="other">Weathers FW, Litz BT, Keane TM, Palmieri PA, Marx BP, Schnurr PP (n.d.). <italic>The PTSD Checklist for DSM-5 (PCL-5) &#x02013; Standard</italic>. <ext-link ext-link-type="uri" xlink:href="https://www.ptsd.va.gov/">https://www.ptsd.va.gov/</ext-link></mixed-citation></ref><ref id="CR12"><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkerson</surname><given-names>AK</given-names></name><name><surname>McRae-Clark</surname><given-names>AL</given-names></name></person-group><article-title>A review of sleep disturbance in adults prescribed medications for opioid use disorder: potential treatment targets for a highly prevalent, chronic problem</article-title><source>Sleep Med</source><year>2021</year><volume>84</volume><fpage>142</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.sleep.2021.05.021</pub-id><pub-id pub-id-type="pmid">34153796</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Wilkerson AK, McRae-Clark AL (2021) A review of sleep disturbance in adults prescribed medications for opioid use disorder: potential treatment targets for a highly prevalent, chronic problem. Sleep Med 84:142&#x02013;153. 10.1016/j.sleep.2021.05.021<pub-id pub-id-type="pmid">34153796</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>